U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.22
    +0.13 (+0.55%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.1819%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.1088%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.2696%)
     
  • BTC-USD

    19,274.17
    +67.36 (+0.35%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update

Editas Medicine, Inc.
·1 min read

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2020.

Conference Call & Webcast Details

Date:

Thursday, November 5, 2020

Time:

5:00 pm Eastern Time

Toll Free:

(844) 348-3801

International:

(213) 358-0955

Conference ID:

9992536

Webcast:

https://edge.media-server.com/mmc/p/b5td2coz

A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com